Italy approves law on controversial stem cell therapy

Image
AFP Rome
Last Updated : May 23 2013 | 1:40 AM IST
Italian lawmakers today gave their final approval to a law that allows limited use of a controversial type of stem cell therapy which has been condemned by many scientists but has given hope to families of terminally-ill children.
The law gives the go-ahead for therapy being carried out by the Stamina Foundation on dozens of patients to continue, and allows for an 18-month period of clinical trials for the procedure, which had previously been blocked by Italian authorities.
The bill was amended from an earlier version and states the therapy must be carried out under regulatory oversight and using cells made according to the Good Manufacturing Practice (GMP) which the Stamina Foundation has not adhered to.
The Stamina Foundation says its treatment is based on mesenchymal stem cells and could treat diseases like spinal cord injury and motor neurone disease.
But leading scientists have warned that there is no evidence to suggest the treatment could work and no way to know that it will not cause harm.
Umberto Galderisi from the University of Naples and president of Stem Cell Italy, is among critics of the bill.
He said the clinical trials would "never have been allowed" if scientific accepted practice had been followed.
"This is legislating on the basis of public opinion. It means exploiting suffering. Patients are not lab rats," he told AFP, adding there were "no scientific certainties" the therapy could work.
"We do not want Italy to become one of those countries like China or Ukraine where there are untested scientific trials," he said.
Patients lobbied for the therapy to be given the go-ahead, receiving support from various celebrities including actress Gina Lollobrigida.
At one demonstration, protesters wore T-shirts with the slogan: "Yes to Stamina, Yes to Life".
The association Stem Cell Research Italy has branded the new law as "unacceptable" saying the therapy was not backed up by clinical data published in peer-reviewed academic journals.
US journal Nature said it was a "rogue" therapy.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: May 23 2013 | 1:40 AM IST

Next Story